Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 537: | Line 537: | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders | ||
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia | ||
|Antibody-mediated platelet destruction | |Antibody-mediated platelet destruction | ||
| | | | ||
Line 568: | Line 567: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE) | ! colspan="2" align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE) | ||
| | |||
| | | | ||
| | | | ||
Line 599: | Line 597: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS) | ! colspan="2" align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS) | ||
|autoantibody-mediated syndrome | |||
! | ! | ||
! | ! | ||
Line 630: | Line 627: | ||
! | ! | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Felty's syndrome | ! colspan="2" align="center" style="background:#DCDCDC;" + |Felty's syndrome | ||
!splenomegaly | !splenomegaly | ||
! | ! | ||
Line 952: | Line 948: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia | ||
| | | | ||
| | | | ||
Line 983: | Line 978: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy | ||
| | | | ||
| + | | + | ||
Line 1,014: | Line 1,008: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Radiation therapy | ! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy | ||
|Predictable, dose-dependent myelosuppression | |Predictable, dose-dependent myelosuppression | ||
| + | | + | ||
Line 1,077: | Line 1,070: | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI | ||
! align="center" style="background:#DCDCDC;" + |Chronic liver disease | ! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease | ||
| | | | ||
| + | | + | ||
Line 1,108: | Line 1,100: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Portal hypertension | ! colspan="2" align="center" style="background:#DCDCDC;" + |Portal hypertension | ||
| | | | ||
| | | | ||
Line 1,172: | Line 1,163: | ||
|- | |- | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular | ||
! align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
Line 1,203: | Line 1,193: | ||
! | ! | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Aortic aneurysm | ! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
Line 1,234: | Line 1,223: | ||
! | ! | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass | ! colspan="2" align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
Line 1,266: | Line 1,254: | ||
|- | |- | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! align="center" style="background:#DCDCDC;" + |Alcohol | ! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol | ||
! | ! | ||
!+ | !+ | ||
Line 1,297: | Line 1,284: | ||
! | ! | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Post-transfusion purpura | ! colspan="2" align="center" style="background:#DCDCDC;" + |Post-transfusion purpura | ||
!immune-mediated platelet destruction | !immune-mediated platelet destruction | ||
! | ! | ||
Line 1,328: | Line 1,314: | ||
! | ! | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia | ||
! | ! | ||
! | ! |
Revision as of 22:16, 14 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | |||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | BT | UA | ||||||||||||||||
Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Plt | HB | WBC | |||||||||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | |||||||||||||||||||||||||||
Aplastic anemia | + | |||||||||||||||||||||||||||||
Acute leukemia | + | |||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | Diagnosis of exclusion | ||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | ||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | |||||||||||||||||||||||||||||
DIC | ||||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | an autoimmune mechanism | + | |||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | + | Moderate to severe | - | |||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | |||||||||||||||||||||||||||||
Felty's syndrome | splenomegaly | |||||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | |||||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | ||||||||||||||||||||||||||||
Tick-borne infection | + | |||||||||||||||||||||||||||||
Viral infections | HIV |
|
+ | |||||||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | |||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Medication/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | + | ||||||||||||||||||||||||||
Heparin-induced thrombocytopenia | + | |||||||||||||||||||||||||||||
Cytotoxic chemotherapy | + | |||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | ||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
GI | Chronic liver disease | + | Mild | |||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||||
Category | Condition | Mechanism | Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | Age range | History | Severity | Fever | Rash | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | BT | UA | Imaging | Gold standard | Associated findings | |
Vascular | Giant capillary hemangioma | platelet destruction | + | |||||||||||||||||||||||||||
Aortic aneurysm | platelet destruction | + | ||||||||||||||||||||||||||||
Cardiopulmonary bypass | platelet destruction | + | ||||||||||||||||||||||||||||
Other | Alcohol | + | ||||||||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction | |||||||||||||||||||||||||||||
Gestational thrombocytopenia | + |